Lincoln Pharmaceuticals gets nod to manufacture HCQ to fight COVID 19

27 Apr 2020 Evaluate

Lincoln Pharmaceuticals has received approval to manufacture Hydroxychloroquine (HCQ) among other critical drugs to fight COVID 19. The company has received approval from Food & Drug Control Administration, Gujarat to manufacture varied dosages of Hydroxychloroquine Tablets and Hydroxychloroquine Sulfate Tablets among others at its plant in Khatraj in Ahmedabad.

After necessary approval from Directorate General of Foreign Trade (DGFT) company will be able to export these products. Food & Drug Control Administration, Gujarat approved manufacture of Hydroxychloroquine Sulfate Tablets USP in 200 MG, 300 MG and 400 MG dosages and Hydroxychloroquine Tablets IP in 200 MG, 300 MG and 400 MG dosages respectively from company’s Khatraj facility.

Lincoln Pharmaceuticals is engaged in the manufacture and marketing of affordable therapeutic products. The product range of the company includes Tablets, Capsules, Injectable, Syrups and Ointments.

Lincoln Pharma Share Price

617.50 -0.15 (-0.02%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.